![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EMA Allows Labeling Flexibilities for COVID-19 Therapeutics
EMA Allows Labeling Flexibilities for COVID-19 Therapeutics
![EMA_Logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/EMA_Logo.gif?t=1579219264&width=430)
March 18, 2021
The European Medicines Agency (EMA), which eased certain labeling requirements for COVID-19 vaccines in December, now says some of the same product labeling flexibilities may apply to COVID-19 therapeutics.
The agency said COVID-19 therapeutics can use English-language-only packaging in member states if the products meet certain criteria, such as being a prescription-only drug that is also a candidate for conditional marketing authorization.
The eased labeling requirements are “reserved for medicines with an important role in tackling the pandemic,” including products under rolling review, EMA said.
Upcoming Events
-
21Oct